BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on the stock and has a $143.00 price target.
Tazeen Ahmad has given his Buy rating due to a combination of factors, primarily focusing on the promising clinical data for BioNTech’s BNT327 in small-cell lung cancer (SCLC). The phase 2 trial results for BNT327, in combination with chemotherapy, showed a higher confirmed objective response rate and longer median progression-free and overall survival compared to existing treatments. These results suggest that BNT327 has the potential to surpass the current standard of care, although further validation through ongoing global phase 3 trials is necessary.
Additionally, the potential for BNT327 to become a significant revenue generator for BioNTech is highlighted, as it represents a multibillion-dollar opportunity. The consistent safety profile and encouraging results across different indications reinforce confidence in BNT327’s prospects. Despite the challenges of cross-trial comparisons and the need for further clinical validation, the positive data and ongoing trials underpin the Buy rating with a price objective of $143.
In another report released on March 26, Deutsche Bank also maintained a Buy rating on the stock with a $140.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.